30 results about "Intraocular fluid" patented technology

The present invention provides a device for use in an eye with elevated intraocular pressure or glaucoma, the device comprising a subconjunctival conformer shaped to conform to the eye wall and a fluid director that directs or facilitates the flow of intraocular fluid out of the eye and into the subconjunctival or retrobulbar space. The present invention also provides a method of lowering intraocular pressure using the device of the present invention.

An ocular implant comprising a shunt and a fluid absorbing conduit for reducing intraocular pressure, and optionally comprising a biodegradable ring.

An ocular drainage system is provided for treating diseases that produce elevated intraocular pressures, such as glaucoma, wherein the system includes an implantable device and an external control unit. The implantable device includes a non-invasively adjustable valve featuring at least one deformable tube and a disk rotatably mounted within a housing, such that rotation of the disk using the external control unit causes the disk to apply a selected amount of compression to the deformable tube, thereby adjusting the fluidic resistance of the deformable tube and regulating the intraocular pressure.

The present invention relates to the non-invasive optical measurement of glucose and other dissolved substances in human or animal intraocular fluid. For this purpose, a method and devices for carrying out the method are proposed. The method according to the invention takes advantage of the fact that the wave dependence of optical activity is fundamentally different from corneal birefringence. The optical activity of substances dissolved in the intraocular fluid, such as glucose, lactate, ascorbic acid or amino acids, is scaled as a first approximation with the reciprocal value of the wavelength square. Upon closer review, higher orders must be taken into consideration and effectively an exponent varying from a value of 2 may occur. For glucose, the exponent shall be denoted as 2+x_G, with the value x_G being approximately 0.2. Accordingly, the exponents for lactate are denoted as 2+x_Lak, for ascorbic acid as 2+x_Asc and for amino acids as 2+x_Am. In contrast, corneal birefringence is scaled with the reciprocal value of the wavelength and therefore behaves considerably different from the optical activity. For the method according to the invention, a physical model is used, which describes the influence on the polarization of measurement radiation by the components of the eye, particularly by the intraocular fluid and the cornea.

Apparatus and methods are provided for treating diseases that produce elevated intraocular pressures, such as glaucoma, wherein the device operates on the principles of a Starling resistor, and includes a housing, a deformable structure and a spring mounted within a housing, such that the spring applies a substantially constant spring force over a predetermined working range on the deformable structure to thereby self-regulate flow of fluid through the deformable structure.

The invention discloses a special phacoemulsification instrument for ophthalmic treatment. The phacoemulsification instrument comprises an ultrasonic handle and a controller, the ultrasonic handle isconnected with a peristaltic pump, the peristaltic pump is connected with a general assembler, an emulsion bottle, a pressure sensor and an ultrasonic generator are respectively connected outside thatgeneral assembler, the pressure sensor is connected with a negative pressure generator, a waste liquid recovery device is arranged outside the negative pressure generator, the structure is simple, the structure is clear and easy to understand, the problems of large operation incision, uncontrollable intraocular pressure and low intelligence degree are solved, the heating of an ultrasonic probe during operation is avoided, the anterior chamber depth is maintained constant, the invention has multiple functions, small incision, good treatment effect and intelligence, and is suitable for microwave treatment fields. In addition, it is very convenient to adjust the suction of chylous fluid and the injection of intraocular perfusion fluid through flow regulator, thus maintaining the dynamic balance of intraocular fluid, which is worth popularizing.

The invention discloses an LAMP primer combination for detecting 5 gram-positive bacteria in intraocular fluid and an application thereof. The primer combination provided by the invention firstly is composed of 30 DNA molecules shown in a sequence 1 to 30. The primer combination can be applied for detecting whether to-be-tested bacteria are staphylococcus epidermidis, staphylococcus aureus, enterococcus faecalis, enterococcus faecium, or streptococcus pyogenes, and can be applied for detecting whether to-be-tested samples contain staphylococcus epidermidis and/or staphylococcus aureus and/or enterococcus faecalis and/or enterococcus faecium and/or streptococcus pyogenes. The primer combination provided by the invention is used for detecting 5 gram-positive bacteria in the intraocular fluid, has high specificity and sensitivity, can realize simple, rapid and accurate detection, and has great promotion value.

Apparatus and methods are provided for treating diseases that produce elevated intraocular pressures, such as glaucoma, wherein the device includes a housing shell defining a cavity between a first end and a second end of the housing shell, and an elastic membrane disposed within the cavity to divide the cavity into a fluidic channel that permits a flow of fluid from the first end to the second end and a sealed cavity. The elastic membrane deforms to change the volume of the sealed cavity responsive to pressure fluctuations between the first and second ends, thereby varying the fluidic resistance of the flow of fluid through the fluidic channel.

The invention discloses an LAMP primer combination for detecting 4 gram-negative bacteria in intraocular fluid and an application thereof. The primer combination provided by the invention firstly is composed of 24 DNA molecules shown in a sequence 1 to 24. The primer combination can be applied for detecting whether to-be-tested bacteria are escherichia coli, pseudomonas aeruginosa, klebsiella pneumoniae or acinetobacter baumannii, and can be applied for detecting whether to-be-tested samples contain escherichia coli and/or pseudomonas aeruginosa and/or klebsiella pneumoniae and/or acinetobacter baumannii. The primer combination provided by the invention is used for detecting 4 gram-negative bacteria in the intraocular fluid, has high specificity and sensitivity, can realize simple, rapid and accurate detection, and has great promotion value.

Ocular drainage systems are disclosed. In various embodiments, the ocular drainage systems include a compliant fluid conduit that is configured to be implanted within a biological tissue, such as tissues of an eye. The compliant fluid conduit includes an exterior having a microstructure that is configured to permit cellular ingrowth. A first end of the compliant fluid conduit is configured to be inserted into an eye of a patient to allow ocular fluid to drain from the eye, and a second end of the compliant fluid conduit is configured to be inserted into an ocular venous system of the patient to allow the ocular fluid drained from the eye to flow directly into the ocular venous system.

The present invention relates to an ocular device for regulating intraocular fluid pressure comprising or consisting of a tubular body wherein the inner surface of the tubular body or the inner and outer surface is/are coated with covalently immobilized hyaluronic acid (HA). In more specific embodiments, the tubular body comprises or consists of a biocompatible material selected from the group comprising a biocompatible metal such as titanium, ceramics, glass, polymers and composites thereof, and the immobilized hyaluronic acid molecules are linked with further HA molecules to form a HA hydrogel. The ocular device is a stent free from mechanical valves or other mechanical means for actively regulating the flow of intraocular fluid.

A device (100) is provided for treating diseases that produce elevated intraocular pressures, such as glaucoma, wherein the device (100) includes a housing shell (101) defining a cavity (107) between a first end (102) and a second end (104) of the housing shell (101), and an elastic membrane (110) disposed within the cavity (107) to divide the cavity (107) into a fluidic channel (106) that permits a flow of fluid from the first end (102) to the second (104) end and a sealed cavity (112). The elastic membrane (110) deforms to change the volume of the sealed cavity (107) responsive to pressure fluctuations between the first and second ends (102, 104), thereby varying the fluidic resistance of the flow of fluid through the fluidic channel (106).

The invention discloses a novel drug for treating eye disease. The drug is prepared from the following raw materials in parts by weight of 0.001-0.1 of aspartic acid, 0.001-0.1 of threonine, 0.001-0.1of serine, 0.001-0.1 of cystine, 0.001-0.1 of valine, 0.001-0.1 of methionine, 0.001-0.1 of isoleucine, and 0.001-0.1 of leucine. The invention relates to the technical field of medicine. The novel drug for treating eye diseases has the effects of promoting metabolism of the eye tissue, accelerating scar healing, absorbing inflammation exudation, and promoting regeneration of skin tissues on thecornea and the like, the ciliary nutrition conditions can be rapidly improved, the ciliary muscle spasm can be released, reflux of liquid from inside of eyes to outside is accelerated, the effect is quick and obvious, and the effects of relieving internal eye high pressure, rapidly restraining visual fatigue, quickly correcting vision and binocular vision dysfunction can be achieved, and the effects of rapidly improving human immunity, treating both symptoms and root causes, being difficult to relapse, free of toxic and side effects and the like can be realized; and the novel drug can be usedfor effectively treating myopia, presbyopia, visual fatigue and various chronic ophthalmic diseases.

The invention discloses an LAMP primer combination for detecting candida albicans in intraocular fluid and an application thereof. The primer combination provided by the invention consists of six single-stranded DNA molecules shown in a sequence 1 to 6. The invention also provides the application of the primer combination in detection of candida albicans. The invention also provides a method for detecting whether a to-be-tested sample is infected with candida albicans. The LAMP primer and method can be applied for detecting candida albicans quickly and accurately.

The invention provides a device for intraoperative intraocular pressure measurement, and relates to the field of medical instruments. The device for intraoperative intraocular pressure measurement comprises monitoring equipment, a pressure measuring pipeline, a connecting device and an intraocular puncture device, wherein the monitoring equipment comprises an electrocardiograph monitor, a pressure converter is fixedly connected to the interior of the electrocardiograph monitor, a pressure monitoring module is fixedly connected to the position, located on the top side of the pressure converter, in the electrocardiogram monitor, and the output end of the pressure monitoring module is electrically connected with the input end of the pressure converter. By arrangement of the monitoring equipment, the pressure measuring pipeline and the intraocular puncture device, intraocular pressure changes can be monitored in real time in the puncture process and the anti-glaucoma operation process, when the pressure is too high, a puncture needle head is pressed to discharge intraocular fluid to reduce the intraocular pressure, when the intraocular pressure is too low, a continuous flushing system pushes and injects liquid to increase the intraocular pressure to an ideal level, and the device is convenient to use and simple to operate.

The present disclosure generally relates to devices and methods for intraocular fluid delivery. Embodiments described herein provide improved mechanisms for precise delivery of therapeutic agents to intraocular tissues by utilizing a foot controller to wirelessly control a handheld injection device. The utilization of a remote foot controller to control the injection reduces or eliminates uneven application of injection force and hand tremor caused by hand-triggered devices, thus enabling precise position and flow rate control and reducing the risk of tissue damage.

The invention discloses a set of LAMP primers for detecting EB viruses in an intraocular fluid and application thereof. The LAMP primers are composed of six single-stranded DNA molecules shown in sequences 1-6. The invention further discloses the application of the LAMP primers and a kit containing the LAMP primers. Experiments show that the LAMP primers have high specificity and high sensitivitywhen used for detecting the EB viruses, and the applied LAMP primers and method can rapidly and accurately detect the EB viruses.

The invention discloses LAMP primers for detecting mycobacterium tuberculosis in an intraocular fluid and application thereof. The LAMP primers are composed of six single-stranded DNA molecules shownin sequences 1-6. The invention further discloses the application of the LAMP primers and a kit containing the LAMP primers. Experiments show that the LAMP primers have high specificity and high sensitivity when used for detecting the mycobacterium tuberculosis, and the applied LAMP primers and method can rapidly and accurately detect the mycobacterium tuberculosis.